In PCa, prostatic acid phosphatase (PAP) is a promising target antigen because its expression is exclusive to prostatic tissue, both normal and malignant, and has a rodent homolog for preclinical models [80,81]. Here, ACP3 is linked to posterior cortical atrophy.